Kepler Capital Markets Downgrades Smith & Nephew SNATS (NYSE:SNN) to Hold

Smith & Nephew SNATS (NYSE:SNN) was downgraded by stock analysts at Kepler Capital Markets from a “buy” rating to a “hold” rating in a research note issued on Thursday, Marketbeat Ratings reports.

Several other equities analysts have also issued reports on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Monday, April 20th. Canaccord Genuity Group decreased their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Sanford C. Bernstein set a $31.85 price target on Smith & Nephew SNATS in a research report on Monday, May 11th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. One equities research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Smith & Nephew SNATS presently has an average rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Trading Up 2.0%

Shares of NYSE:SNN opened at $29.94 on Thursday. The firm has a 50 day simple moving average of $31.47 and a 200-day simple moving average of $32.92. Smith & Nephew SNATS has a twelve month low of $28.40 and a twelve month high of $38.79. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57.

Smith & Nephew SNATS (NYSE:SNN) last posted its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The company had revenue of $1.60 billion during the quarter. On average, research analysts expect that Smith & Nephew SNATS will post 2.25 EPS for the current year.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several institutional investors and hedge funds have recently made changes to their positions in SNN. Garner Asset Management Corp purchased a new position in Smith & Nephew SNATS during the 4th quarter valued at about $27,000. Arax Advisory Partners grew its position in shares of Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Smith & Nephew SNATS in the fourth quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Smith & Nephew SNATS during the 3rd quarter worth approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Smith & Nephew SNATS in the 4th quarter valued at approximately $43,000. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.